<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872023</url>
  </required_header>
  <id_info>
    <org_study_id>35RC17_8825_IMMUNOMYELO</org_study_id>
    <nct_id>NCT04872023</nct_id>
  </id_info>
  <brief_title>Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression</brief_title>
  <acronym>IMMUNO-MYELO</acronym>
  <official_title>Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The myeloma microenvironment is the target of many drugs in development, and it is unclear&#xD;
      how they can be combined with reference treatments such as lenalidomide. This pilot study&#xD;
      consists of an extensive phenotypic characterisation of the impact of lenalidomide combined&#xD;
      with dexamethasone on the bone marrow microenvironment of a homogeneous cohort of&#xD;
      non-pretreated MM patients. Blood sampling will be systematically performed in a matched&#xD;
      fashion to monitor the general effect of lenalidomide on the immune system and to detect&#xD;
      possible peripheral markers.&#xD;
&#xD;
      This study will provide rational guidance for future combination therapies with lenalidomide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the significant increase in the number of therapeutic combinations targeting the tumour&#xD;
      microenvironment, it is crucial to better understand the effect of reference myeloma&#xD;
      treatments on the different immune populations present in the tumour in order to rationally&#xD;
      optimise the combination with new strategies under development. In addition, the&#xD;
      identification of biomarkers in the circulating blood that can predict/monitor the impact of&#xD;
      new therapies on the immune response is a major challenge.&#xD;
&#xD;
      This pilot study consists of an extensive phenotypic characterisation of the impact of&#xD;
      lenalidomide combined with dexamethasone on the bone marrow microenvironment of a homogeneous&#xD;
      cohort of non-pretreated MM patients. Blood sampling will be systematically performed in a&#xD;
      matched fashion to monitor the general effect of lenalidomide on the immune system and to&#xD;
      detect possible peripheral markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of HLA-DR on medullary T-lymphocytes</measure>
    <time_frame>1 month</time_frame>
    <description>Changed expression of HLA-DR on medullary T-lymphocytes after exposure to lenalidomide-dexamethasone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation status of biological markers</measure>
    <time_frame>1 month</time_frame>
    <description>Presence of active protein markers and immune checkpoints by medullary immune cell subpopulations.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will have a extra blood sampling before first cycle of treatment and after one cycle. They also have an extra bone marrow sampling after the first cycle of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and bone marrow sampling</intervention_name>
    <description>Blood and bone marrow sampling</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with newly diagnosed multiple myeloma;&#xD;
&#xD;
          -  Patient not eligible for intensive treatment;&#xD;
&#xD;
          -  Patient for whom first-line treatment with Lenalidomide-Dexamethasone will be&#xD;
             initiated;&#xD;
&#xD;
          -  Patient accepting the performance of an additional myelogram at the end of the 1st&#xD;
             treatment cycle.&#xD;
&#xD;
          -  Patient aged 18 years or older;&#xD;
&#xD;
          -  Patient who has given free, informed and written consent;&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
          -  For women of childbearing age, use of effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with relapsed multiple myeloma;&#xD;
&#xD;
          -  Patient eligible for intensive treatment;&#xD;
&#xD;
          -  Patient for whom chemotherapy involves treatment other than&#xD;
             Lenalidomide-Dexamethasone;&#xD;
&#xD;
          -  Patient with a contraindication to lenalidomide treatment&#xD;
&#xD;
          -  Pregnant or breastfeeding woman;&#xD;
&#xD;
          -  Person subject to legal protection (safeguard of justice, curatorship,guardianship) or&#xD;
             person deprived of liberty.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Decaux, Pr</last_name>
    <phone>2 99 28 76 92</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.decaux@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Decaux</last_name>
      <email>olivier.decaux@chu-rennes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

